2.42
  Price6.61%   +0.1500
(After Hours: 2.40 -0.0200 -0.83%)
Jun-07-22 07:29AM Implied Volatility Surging for Ocugen (OCGN) Stock OptionsZacks Investment Research
Jun-02-22 10:08AM Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022Benzinga
08:45AM Stock Market Plunge: 2 Stocks to Avoid Right NowThe Motley Fool
May-28-22 06:30AM Will This Beaten-Down Stock Bounce Back? 3 Things to KnowThe Motley Fool
May-26-22 11:07AM 2 Struggling Stocks That Aren't Likely to Recover Anytime SoonThe Motley Fool
May-24-22 11:30AM Ocugen (OCGN) Covaxin Studies Clinical Hold Lifted by FDAZacks Investment Research
07:56AM Philadelphia reinstates face-mask mandate for students and teachers, and WHO head warns pandemic is ‘most certainly not over’MarketWatch
May-24-22 07:11AM Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) RecognitionGlobeNewswire Inc.
May-23-22 02:12AM Philadelphia reinstates face-mask mandate for students and teachers, and WHO head warns pandemic is ‘most certainly not over’MarketWatch
10:11AM Philadelphia reinstates face-mask mandate for students and teachers, and WHO head warns pandemic ‘most certainly not over’MarketWatch
May-23-22 07:34AM Ocugen, Inc. to Present at H.C. Wainwright Global Investment ConferenceGlobeNewswire Inc.
06:36AM Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)GlobeNewswire Inc.
May-18-22 06:30AM Is Ocugen Finally on the Way to Vaccine Revenue?The Motley Fool
May-13-22 07:10AM Where Will Ocugen Be in 1 Year?The Motley Fool
May-09-22 07:05AM Could Novavax Stock Help You Retire a Millionaire?The Motley Fool
May-06-22 12:30PM Ocugen, Inc. (OCGN) Q1 2022 Earnings Call TranscriptThe Motley Fool
07:45AM Ocugen (OCGN) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research
May-06-22 06:33AM Ocugen Provides Business Update and First Quarter 2022 Financial ResultsGlobeNewswire Inc.
May-02-22 07:37AM Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial ResultsGlobeNewswire Inc.
Apr-30-22 11:15AM 2 Small-Cap Stocks With Monster Upsides, According to Wall StreetThe Motley Fool
Apr-29-22 11:36AM Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual MeetingGlobeNewswire Inc.
Apr-28-22 11:00AM Is It Too Late to Buy Ocugen Stock?The Motley Fool
09:05AM The FDA Just Sent Ocugen a Warning. Should Investors Care?The Motley Fool
Apr-27-22 05:06AM 3 Moonshot Stocks With Upside of Up to 709%, According to Wall StreetThe Motley Fool
Apr-25-22 07:33AM Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical TrialGlobeNewswire Inc.
Apr-19-22 05:32AM Ocugen, Inc. to Present at NobleCon18GlobeNewswire Inc.
05:21AM 4 Ultra-Popular Stocks to Avoid Like the PlagueThe Motley Fool
Apr-18-22 07:11AM Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North AmericaGlobeNewswire Inc.
Apr-17-22 11:30AM 2 Red Flags for Ocugen's FutureThe Motley Fool
Apr-14-22 01:34AM Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & MoreZacks Investment Research
Apr-13-22 09:55AM Ocugen (OCGN) Stock Down as FDA Puts Hold on Covaxin StudyZacks Investment Research
Apr-12-22 08:31AM Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)GlobeNewswire Inc.
Apr-06-22 05:21AM 3 COVID-19 Stocks With Monster Upside of Up to 355%, According to Wall StreetThe Motley Fool
Apr-04-22 04:41AM Hot Biotech Penny Stocks to Watch During the First Full Week of April PennyStocks
Apr-01-22 11:19AM Why Ocugen Stock Is Jumping TodayThe Motley Fool
07:37AM Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal DegenerationGlobeNewswire Inc.
Mar-30-22 05:06AM 3 Growth Stocks With Monster Upside of Up to 331%, According to Wall StreetThe Motley Fool
Mar-26-22 07:00AM Is Johnson & Johnson Setting a Dangerous Precedent for the Healthcare Industry?The Motley Fool
Mar-24-22 11:37AM Is It Too Late to Buy Vaxart Stock?The Motley Fool
05:56AM Is It Time to Buy COVID-19 Vaccine Stocks Again?The Motley Fool
Mar-23-22 07:44AM Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of DirectorsGlobeNewswire Inc.
Mar-21-22 06:36AM Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, FinanceGlobeNewswire Inc.
08:43AM Here's what it will take to make stocks a 'great' buying opportunity, says this strategistMarketWatch
Mar-21-22 06:08AM Here's what it will take to make stocks a 'great' buying opportunityMarketWatch
06:00AM 1 Green Flag for Ocugen in 2022, and 1 Red FlagThe Motley Fool
Mar-18-22 05:56AM Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.
Mar-17-22 08:10AM 4 Numbers That Make Ocugen an Extremely Risky BuyThe Motley Fool
Mar-15-22 11:48AM Why Ocugen Stock Is Jumping TodayThe Motley Fool
11:45AM Wall Street Thinks This Stock Could Soar by 242%; Here's Why It's Not a BuyThe Motley Fool
Mar-14-22 06:15AM Is It Too Late to Buy Ocugen Stock?The Motley Fool
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Cap:    |  Volume (24h):